Newer EGFR pill for advanced lung cancer with specific mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell lung cancer that has not been treated yet.
- Your cancer has a specific genetic change called a PACC mutation (a type of EGFR mutation).
- You are age 21 or older and your overall health is good enough for daily activities (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your kidney, liver, and blood counts are within adequate ranges.
- You are not pregnant, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new targeted pill called TY-9591 combined with chemotherapy as a first treatment for advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the current standard of care.
This study tests an oral pill (BPI-361175) for people with advanced non-small cell lung cancer that has specific EGFR mutations, especially when standard EGFR-targeted treatments are no longer working. The goal is to see if it can shrink tumors or slow growth.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial tests whether removing the main lung tumor with surgery, combined with an EGFR-targeted pill, can help people with stage IV lung cancer that has a specific EGFR mutation. The goal is to improve outcomes compared with medication alone.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.